{"id":"W2576796004","doi":"10.1136/esmoopen-2016-000118","title":"Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy","year":2016,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Samsung; Genentech; Eisai; Amgen; Ariad Pharmaceuticals; Boehringer Ingelheim; Helsinn; Clovis Oncology; Sanofi; Helsinn Therapeutics; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Atezolizumab; Medicine; Ramucirumab; Nivolumab; Oncology; Internal medicine; Chemotherapy; Lung cancer; Immunotherapy; Nintedanib; Cancer; Lung","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003181135,0.0001694602,0.0002513056,0.00007565716,0.00006717673,0.00002945389,0.0001154714,0.00004824859,0.0004577495],"category_scores_gemma":[0.00001806855,0.00009817385,0.00003236573,0.0001340331,0.00006965934,0.0003992289,0.00004450715,0.00006374076,0.00002674562],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002532371,"about_ca_system_score_gemma":0.0001297848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002255446,"about_ca_topic_score_gemma":0.001277452,"domain_scores_codex":[0.9990777,0.0000127806,0.0001703904,0.0003193817,0.0002034471,0.0002162731],"domain_scores_gemma":[0.9993609,0.00002717112,0.00009498088,0.0002638251,0.0001522718,0.0001008358],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003034829,0.001257925,0.949778,0.00001224898,0.0002263533,0.00001514404,0.001689987,0.00001061185,0.00002002187,0.00001355895,0.0002086983,0.04373262],"study_design_scores_gemma":[0.0277997,0.0005855485,0.9658656,0.0005456827,0.00009456699,0.000001404816,0.00005846029,0.0000176017,0.0006316869,0.00002806279,0.004222942,0.0001487437],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900569,0.000009931013,0.0005733221,0.0021585,0.00004902873,0.002979052,0.0001407658,0.00002417499,0.004008332],"genre_scores_gemma":[0.9912311,0.00001115323,0.002744854,0.0005765142,0.00002571231,0.0008232355,0.0001172762,0.00003970617,0.004430481],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04358388,"threshold_uncertainty_score":0.5012036,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01509609863842119,"score_gpt":0.3330041230318293,"score_spread":0.3179080243934081,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}